4Leckman JF, Price RA, Walkup JT, et al. Nongenetic factors in Gilles de la Tourette's syndrome. Arch Gen Psychiatry, 1987,44(1):100.
5Church A J, Dale RC, Lees AJ, et al. Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry, 2003, 74(5):602.
6Singer HS, Loiselle C. PANDAS. A commentary. J Psychosom Res, 2003, 55(1):31.
7Hallett JJ, Harling-Berg CJ, Knopf PM, et al. Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction . J Neuroimmunol,2000,111:195.
8Wendlandt JT, Grus FH, Hansen BH, et al. Striatal antibodies in children with Tourette's syndrome: multivariate discriminant analysis of IgG repertoires. J Neuroimmunol, 2001, 119:106.
7Albin R L,Koeppe R A,Bohnen N I,et al.Increased ventral striatal monoaminerglc innervationin Tourette syndrome[J].Neurology,2003,61(3):310-315.
8Ogawa N,Haba K,Asanuma M,et al.Long-lasting effect of ceruletide on dyskinesia and monoaminergic neuronal pathways in rats treated with iminodipropionitrile[J].Brain Res,1991,556(2):271-279.
9Tariq M,Khan H A,Rehana Z,et al.Proglumide,a cholecystokinin receptor antagonist,exacerbates β,β'-iminodipropionitrile-induced dyskinetic syndrome in rats[J].Neurotoxicol Teratol,1998,20(5):571-579.
10White H S,Smith M D,Wilcox K S.Mechanisms of action of antiepileptic drugs[J].Int Rev Neumbiol,2007,81(1):85-110.
